Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer. Garbe C, et al. Among authors: keilholz u. J Clin Oncol. 2020 Aug 1;38(22):2543-2551. doi: 10.1200/JCO.19.03034. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530760 Free PMC article.
Functional CCR9 expression is associated with small intestinal metastasis.
Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: keilholz u. J Invest Dermatol. 2004 Mar;122(3):685-90. doi: 10.1111/j.0022-202X.2004.22315.x. J Invest Dermatol. 2004. PMID: 15086554 Free article.
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Keilholz U, et al. J Clin Oncol. 2005 Sep 20;23(27):6747-55. doi: 10.1200/JCO.2005.03.202. J Clin Oncol. 2005. PMID: 16170182 Clinical Trial.
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. Eggermont AM, et al. Among authors: keilholz u. Lancet. 2005 Oct 1;366(9492):1189-96. doi: 10.1016/S0140-6736(05)67482-X. Lancet. 2005. PMID: 16198768 Clinical Trial.
[Brief guidelines: malignant melanoma of the skin].
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Garbe C, et al. Among authors: keilholz u. J Dtsch Dermatol Ges. 2006 Apr;4(4):344-9. doi: 10.1111/j.1610-0387.2006.05891.x. J Dtsch Dermatol Ges. 2006. PMID: 16638065 Review. German. No abstract available.
424 results